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Abstract
Background: The glucocorticoid receptor (GR) is a transcription factor that regulates gene expression in a ligand-dependent
fashion. This modular protein is one of the major pharmacological targets due to its involvement in both cause and
treatment of many human diseases. Intense efforts have been made to get information about the molecular basis of GR
activity.
Methodology/Principal Findings: Here, the behavior of four GR-ligand complexes with different glucocorticoid and
antiglucocorticoid properties were evaluated. The ability of GR-ligand complexes to oligomerize in vivo was analyzed by
performing the novel Number and Brightness assay. Results showed that most of GR molecules form homodimers inside the
nucleus upon ligand binding. Additionally, in vitro GR-DNA binding analyses suggest that ligand structure modulates GR-
DNA interaction dynamics rather than the receptor’s ability to bind DNA. On the other hand, by coimmunoprecipitation
studies we evaluated the in vivo interaction between the transcriptional intermediary factor 2 (TIF2) coactivator and
different GR-ligand complexes. No correlation was found between GR intranuclear distribution, cofactor recruitment and the
homodimerization process. Finally, Molecular determinants that support the observed experimental GR LBD-ligand/TIF2
interaction were found by Molecular Dynamics simulation.
Conclusions/Significance: The data presented here sustain the idea that in vivo GR homodimerization inside the nucleus
can be achieved in a DNA-independent fashion, without ruling out a dependent pathway as well. Moreover, since at least
one GR-ligand complex is able to induce homodimer formation while preventing TIF2 coactivator interaction, results
suggest that these two events might be independent from each other. Finally, 21-hydroxy-6,19-epoxyprogesterone arises as
a selective glucocorticoid with potential pharmacological interest. Taking into account that GR homodimerization and
cofactor recruitment are considered essential steps in the receptor activation pathway, results presented here contribute to
understand how specific ligands influence GR behavior.
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Introduction
The glucocorticoid receptor (GR) is a ligand-regulated tran-
scription factor, member of the nuclear-receptor (NR) superfamily
that controls gene expression linked to several processes like
inflammation, stress responses, glucose homeostasis, lipid metab-
olism, proliferation and apoptosis development [1]. Due to GR
involvement in the cause and treatment of many human diseases,
it is considered one of the major pharmacological targets. Many
synthetic glucocorticoid drugs, such as dexamethasone (Dex) or
prednisolone, are widely used in the treatment of several
immunological and inflammatory diseases [2]. However, the
desired immunosupresant and anti-inflammatory effects are often
compromised by severe or partially nonreversible side effects [2–
4]. To improve glucocorticoid pharmacological profile, intense
efforts have been made to obtain more information about the
molecular mechanisms that underlie beneficial and unwanted
glucocorticoid properties, and to design new selective compounds.
In the absence of ligand, GR is associated to the hsp90
chaperone heterocomplex and primarily localizes in the cytoplasm
while the GR-ligand complex is mainly nuclear. In the nucleus, the
activated GR regulates gene expression through two main modes
of action [5,6]. A direct mechanism involves GR homodimer
binding to positive or negative Glucocorticoid Response Elements
(GRE) located in the promoter region of target genes, leading to
transcription activation or repression, respectively. On the other
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mechanism by interacting as a monomer with other transcriptional
factors, such as NFkB or AP-1 [7]. Therefore, activated GR
monomers control gene expression by modulating the transcrip-
tional activities of those transcription factors, without direct
binding to DNA. Interestingly, since both GR modes of action
would be independent, it has been postulated that glucocorticoid
desired consequences are associated to the indirect-transrepression
mechanism, while the side effects are associated to the direct
transactivation one. However, this hypothesis is currently under
revision as it was demonstrated that mechanistically, distinct forms
of glucocorticoid-inducible gene expression are critical to the
development of anti-inflammatory effects by repressing inflamma-
tory signaling pathways and inflammatory gene expression at
multiple levels [4,8,9]. Thus, the design of novel GR ligands
should consider a detailed evaluation of which types of GR
conformations relate to which specific transcriptional responses
and functional outcomes.
Like most of the NRs, the GR is a modular protein that is
organized into three major domains: a poorly conserved N-
terminal ligand-independent activation function-1 domain (AF-1),
a highly conserved central DNA-binding domain (DBD) that
recognizes specific GREs in target promoters -plus a dimerization
region-, and a C-terminal ligand-binding domain (LBD) [10,11].
The LBD contains ten a ´-helices that fold into a globular structure,
described as a net enclosing a central hydrophobic ligand-binding
pocket (LBP). According to X-ray crystallography analysis, the
structural plasticity of the LBP allows the binding of ligands with
quite different geometries [12–17]; thus, bulky groups located in
different positions of the steroid, fit into the LBD without affecting
its global conformation. In addition to the LBP, the LBD also
contains a dimerization interface and a hydrophobic domain (AF-
2), involved in the interaction with cofactors. In this way, ligand
structure may influence GR conformational states that would
modulate its ability to homodimerize and/or to recruit either
coactivators or corepressors. In this sense, the understanding of
how specific ligands influence the GR-LBD conformation could be
a key start-point in the rational design of new selective
glucocorticoid receptor modulators (SGRMs) [18].
Despite the fact that little is known about how ligand structure
may affect GR dimerization, some reports have been focused on
the study of GR-LBD/cofactor interactions. Particularly, it is well
known that the p160 GR coactivators family contain multiple
LxxLL motifs in which leucine residues are presented on one face
of the amphipathic helix making it to be in contact with the AF-2
nonpolar groove [12]. Even though this binding site is formed by
residues of helices H3, H4 and H12, its conformation is mainly
determined by the H12 position. Thus, the binding of the pure
agonist Dex induces a GR conformation in which the position of
H12 allows the interaction with coactivators such as the
transcriptional intermediary factor 2 (TIF2) [12,19]. In contrast,
H12 conformation changes when the GR binds the antagonist
RU486, preventing GR-coactivator interaction [19] but allowing
the recruitment of corepressors [20]. Nevertheless, interaction
between TIF2 and GR-RU486 complex has been described
[21,22]. It is noteworthy that the recently obtained GR LBD-
RU486 crystal structure [23] shows that H12 may adopt different
positions upon RU486 binding, explaining at least in part the
complex activity profile of this ligand. On the other hand,
Raaijmakers et al. have recently obtained the crystal structure of
the Progesterone Receptor (PR) LBD-RU486 complex in which
the H12 adopts an agonistic conformation [24].
Although GR homodimerization is considered an essential step
in the GR-mediated gene-activating properties, there is still a
discrepancy in the identification of both, the region involved in
homodimerization and the mechanisms underlying this process. In
this sense, most of the evidences come from in vitro studies, by using
the entire GR protein [25–30] or the GR DBD [31–33]. Although
the DBD mutant (A458T) generates a receptor that would not be
able to homodimerize in vitro [34,35], several evidences suggest
that LBD and AF-1 domains also participate in GR homodimer-
ization [12,29]. In addition, the relationship between GR/GRE
interaction and the GR homodimerization process in vivo still is not
clear [34,36–40] neither is whether the coactivator recruitment
occurs before, during or after GR dimer formation [41–44].
In previous works we studied two glucocorticoid rigid analogs,
21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP) and its 21-
hemisuccinate (21HS-6,19OP). 21OH-6,19OP is a specific GR
antagonist that lacks the bulky substituent at C-11 found in active
antagonists of the GR [45–47]. The introduction of a hemi-
succinate group at the 21-position of this passive antiglucocorticoid
leads to a compound (21HS-6,19OP), which behaves like an
agonist of GR action in direct transactivation assays [48].
Taking into account that the understanding of the molecular
role played by different ligands on coactivator recruitment and
dimer formation is related to the ability of predicting the overall
conformational change of the receptor upon ligand binding; we
had previously used Molecular Dynamics (MD) simulation to
evaluate the dynamic behavior of GR LBD-Dex, GR LBD-21OH-
6,19OP and GR LBD-21HS-6,19OP complexes [47,48]. These
results showed that in the receptor bound to 21OH-6,19OP the
average position of the loop between helices 1 and 3 (H1–H3 loop)
adopts a markedly different conformation compared to the GR
LBD–Dex complex. Since according to several GR LBD crystal
structures the H1–H3 loop is a fundamental region of the
homodimerization interface [17], we proposed that the passive
antagonist mode of action of 21OH-6,19OP would reside at least
in part, in the incapacity of GR-21OH-6,19OP complex to form
functional homodimers [47].
Regarding 21HS-6,19OP, those previous results led us to
propose that the hemisuccinate moiety might play a key role in
stabilizing the receptor active conformation of the dimerization
interface, reversing the changes observed with the antagonist
21OH-6,19OP [48].
In this work, we evaluated the in vivo, in vitro and in silico behavior
of both GR-rigid steroid complexes and we compared them with
GR-Dex and GR-RU486. Using a GFPGR chimera on number
and brightness (N&B) assays we observed that the receptor
dimerizes in the nucleus independently of which ligand is bound.
On the other hand, coimmunoprecipitation assays showed that
coactivator recruitment of the different GR-ligand complexes
depends on ligand structure, being GR LBD-21OH-6,19OP
unable to recruit TIF2. Furthermore, molecular determinants that
may explain the observed experimental data were found by MD
simulations analyzing the interaction of GR LBD-ligand com-
plexes and a peptide corresponding to the TIF2 coactivator.
Finally, transrepression studies showed that GR-21OH-6,19OP
complex inhibits NFkB and AP-1 activities. Together, these results
not only give us insights on glucocorticoid receptor activity
modulation but also propose 21OH-6,19OP rigid steroid as a
putative novel selective glucocorticoid.
Results
Intranuclear distribution of GR-ligand Complexes
We began the study by analyzing the intranuclear distribution
of GR-ligand complexes. Since we used the GFPGR chimera in
several studies, we first evaluated the direct transcriptional activity
GR Activity Modulation
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protein [49]. We confirmed that both agonist Dex and 21HS-
6,19OP induce MMTV-driven luciferase expression in BHK cells
overexpressing GFPGR, although the efficacy of the rigid steroid
agonist was lower than Dex, compared with their relative efficacies
reported previously [48]. On the contrary, the antagonists RU486
and 21OH-6,19OP inhibit Dex mediated GFPGR dependent
gene expression (Figure S1A). Using confocal microscopy, we then
tested the cellular distribution of the different GRGFP-ligand
complexes in Cos-7, BHK and L929 cells. In the absence of
ligand, most of the fluorescence is visualized into the cytoplasm
and upon steroid addition, GR translocates to the nucleus
independently of ligand structure (Figure S1B). These results
indicate that the rigid steroids modulate GFPGR in a similar
fashion as the wild type receptor.
Analysis of the different GFPGR-complexes intranuclear
distribution was performed in Cos-7 cells (Figure 1). When the
rigid steroids are added, fluorescence emitted by GFPGR is
randomly distributed into the nucleus at variance with GR-Dex or
GR-RU486 complexes, which distribute in a punctuate manner,
similar to that described previously [50]. Quantitative measure-
ments for the randomness of the complex distribution were
performed by determining the coefficient of variation number
(CV) according to the method established earlier [51]. Figure 1
shows significant differences among the CVs values of 21OH-
6,19OP (0.17260.005) and Dex (0.20160.009) or RU486
(0.20860.009); being 21HS-6,19OP CV value in-between
(0.18160.008). According to previous works [50], our results
support the idea that the nuclear distribution of GR-ligand
complexes do not relate to their transcriptional activities.
Monomeric activity of GR-ligand complexes
The ability of both rigid ligands to modulate monomer-GR
activities were evaluated by analyzing the complex behavior on
NFkB or AP-1 mediated pathways. BHK cells were cotransfected
either with pRelA expression vector and the reporter pkB-
Luciferase or with pcJun and AP-1-Luciferase reporter vector, and
treated with the different steroids. Figure 2 shows that, similarly to
Dex and RU486, both rigid analogs are able to inhibit NFkB
(Figure 2A) and AP-1 activities (Figure 2B). Therefore, although
GR-21OH-6,19OP - like GR-RU486 complex - is unable to
trigger a direct transcriptional response, it has the ability to act
indirectly as a monomer. On the other hand, the GR-21HS-
6,19OP complex, similarly to GR-Dex, exerts glucocorticoid
effects for both direct transactivation (A ´lvarez et al. [48] and
Figure S1A) and indirect transrepression (Figure 2). Moreover,
considering that 21OH-6,19OP is able to transrepress both AP-1
and NFkB pathways but lacks the ability to induce transactivation
(Figure S1A and also in Vicent et al. [45] and Veleiro et al. [52]);
this steroid arises as a putative dissociated glucocorticoid.
Oligomerization state of GR-ligand Complexes
Since the LBD participates actively in the contact between GR
monomers [12], ligand-induced conformational changes would
affect the ability of GR to form functional homodimers and
consequently to induce direct transcription. We performed in vivo
mapping of GR oligomerization state by using the N&B method
described before [53]. This new technique, based on moment-
analysis, provides the average number of moving, fluorescent
molecules and their brightness at every pixel of images. In the
simplest case the brightness of oligomers formed by n monomers
are n times the brightness of monomers. Therefore, N&B can be
used to obtain the oligomerization state of proteins in living cells
with high spatial resolution [53,54].
Figure 3A shows the real brightness (e) fold increase (i.e.
measure of fluorophore oligomerization) corresponding to
GFPGR protein expressed in different cell types. In the absence
of ligand, e values are similar in nucleus and cytoplasm; indicating
the same GR oligomerization status in both cellular compart-
ments. L929 cells transfected with GFP alone show similar
absolute e values than the unbound GFPGR (data not shown),
strongly suggesting that the inactive GR is mainly a monomer.
Upon Dex addition e values significantly increase (approximately 2
fold) in the nucleus with respect to the cytoplasm in all cells
analyzed (Figure 3A). These results are consistent with GR
transformation and dimerization upon ligand binding. GFP e
Figure 1. Intranuclear distribution of GFPGR. Cos-7 cells
transfected with pEGFPGR were incubated with 10 nM Dex, 10 mM
21OH-6,19OP, 10 mM 21HS-6,19OP or with 1 mM RU486 for at least
40 min at 37 C. Cells were visualized by confocal scanning microscopy.
Images were taken between 40 min-3 h after addition of the steroids.
The figure shows representative cells for each treatment and the
coefficient of variation (CV) quantitation as described in ‘‘Materials and
Methods’’. Bars with different superscript letters are significantly
different from each other (P,0.05).
doi:10.1371/journal.pone.0013279.g001
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GR dependence on the oligomerization status (Figure 3A). The
presence of endogenous GR molecules does not seem to interfere
with the analysis, as e values obtained in L929 or BHK cells are
statistically equal to Cos-7 cells that lack endogenous GR.
Consistently, it was demonstrated that transient transfection of
GFPGR carrying the CMV promoter sequence inevitably results
in an overexpression of GFPGR proteins [55]. Therefore,
assuming that GR homodimers are the maximum oligomerization
status possible for the receptor, theoretically, GR e values should
duplicate if all activated GR particles dimerize upon ligand
binding. In this sense our results suggest that most of GR
molecules dimerize in vivo after Dex treatment, although we can
not empirically dismiss the possibility that higher oligomerization
status may occur. Figure 3B shows a similar increase in e values
between nucleus and cytoplasm when L929 cells are treated with
either of the rigid steroids. However, although RU486 treatment
significantly induces receptor oligomerization, it seems to provoke
less dimer formation. Together, results indicate that the activated
GR particle is able to form oligomers, independently of which
Figure 2. GR-ligand complexes monomeric activity. BHK21 cells were cotransfected with pkB-LUC and pRelA vectors (A), or pAP1-LUCand pcJun vectors
(B). pCMV-LacZ vector were also introduced. Cells were incubated for 18 h with ethanol (Control), 10 nM Dex, 10 mM 21OH-6,19OP, 10 mM 21HS-6,19OP,
and 1 mM RU486. Luciferase activity was measured. After correcting for b-galactosidase activity, values were expressed as % induction relative to the control.
Means 6 S.E. from three independent experiments are shown. Bars with different superscript letters are significantly different from each other (P ,0.05).
doi:10.1371/journal.pone.0013279.g002
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PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13279ligand is bound to the receptor. Moreover, results also imply that
21OH-6,19OP antagonistic effect on gene expression activation
would not be related to the ability of the GR LBD-21OH-6,19OP
complex to form homodimers in the nucleus.
Dynamics of DNA-GR-ligand Complexes interaction
To investigate the influence of ligand-induced GR conforma-
tional changes on the ability of GR to interact with specific GREs,
we performed gel-shift assays with nuclear extracts obtained from
Figure 3. In vivo oligomerization analysis of GFPGR molecules. A. Cos-7, BHK21, and L929 cells transfected with pGFPGR were incubated with
ethanol (Control) or 10 nM Dex for at least 40 min at 37 C. L929 (GFP) indicates cells tranfected with pEGFP and incubated with 10 nM Dex. B. L929
cells transfected with pEGFPGR were incubated with ethanol (Control), 10 nM Dex, 10 mM 21OH-6,19OP, 10 mM 21HS-6,19OP or with 1 mM RU486 for
at least 40 min at 37 C. Images were taken between 40 min-6 h after steroids addition. For each cell (15#n#30 per treatment) the apparent
brightness was calculated as described in ‘‘Materials and Methods’’. The figure shows fold-increase of the real brightness (e) relative to the cytoplasm
for each cell type. Bars with different superscript letters are significantly different from each other (P ,0.05).
doi:10.1371/journal.pone.0013279.g003
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with a radiolabeled GRE-containing oligonucleotide from the
MMTV promoter [28]. As it was previously reported [56–61], cell
extracts prepared in the absence of ligand generate a double
retarded band corresponding to GR-MMTV probe complexes
which does not differ from ligand treated extracts (data not shown).
Given this lack of ligand effects on the GR affinity for GRE-sites, we
investigated whether ligand interaction affects the association/
dissociation rate between GR-ligand complexes and DNA.
According to previously published studies [60], a direct measure-
ment and comparison of the association kinetics for different GR-
ligand/DNA complexes is not feasible, thus we determined the
dissociation kinetics. Radiolabeled probes were incubated with
nuclear extracts containing GR-ligand complexes during 20
minutes, then 2006 excess of specific competitor was added and
reaction aliquotswereloadedat different time pointsonto a running
gel (scheme in Figure 4A). For the comparison of DNA dissociation,
all extracts showed similar DNA binding at the initial time point
prior to addition of excess GRE; thus, the dissociation rates were
independent of the fraction of DNA bound. As already shown [60],
Dex and RU486 have opposite effects on GR-DNA dissociation
kinetics (Figure 4B–C). GR-Dex/DNA complex exhibits the fastest
dissociation kinetics (t1/2=0.5660.05 min) whereas the GR-
RU486/DNA complex shows the slowest (t1/2=2.3360.56 min)
(Figure 4C). However, both rigid analog complexes, GR-21OH-
6,19OP/DNA and GR-21HS-6,19OP/DNA have similar dissoci-
ation kinetics (t1/2=0.9660.08 and 1.0260.13 min., respectively)
indicating that the different abilities of both rigid analogs to
transactivate the MMTV promoter would not be due to the
dynamic of those complexes to bind DNA.
Cofactor interaction
Since the GR ability to induce transcription depends, at least in
part, on the ligand-induced interaction with coactivators, one might
postulate that the reduced transcriptional activation by a selective
compound should indicate an impaired recruitment of coactivators.
PreviousMD simulations showed that the conformationof the AF-2
domain changes in the presence of rigid analogs [47,48] suggesting
that the binding of these steroids could affect GR ability to recruit
TIF2. In order to evaluate GR/TIF2 interaction, we performed co-
transfectionson BHKcells withthe pMMTV-Luciferase reporter in
the presence or absence of pTIF2 expression vector. Therefore, we
analyzed the effect of coactivator overexpression on ligand-
dependent MMTV transcription activation. As expected,
Figure 5A shows that TIF2 potentiates transcriptional activity of
GR agonists; in fact, Dex-induced luciferase expression increases
1.60 fold when pTIF2 vector is co-transfected while 21HS-6,19OP-
induced luciferase expression increases 2.85 fold. However, TIF2
overexpression is not able to generate neither RU486 nor 21OH-
6,19OP agonistic activities. This result would indicate that no
interaction exists between GR-RU486 or GR-21OH-6,19OP
complexes and the TIF2 coactivator, or if an interaction occurs it
would result in a non-functional GR-ligand/TIF2 complex.
Figure 4. Ligand effect on in vitro GR-DNA dissociation. EMSAs were performed using nuclear extracts from BHK21 cells treated with ethanol
(Control), 10 nM Dex, 10 mM 21OH-6,19OP, 10 mM 21HS-6,19OP and 1 mM RU486 for 30 min. Protein extracts incubated with a
32P-radiolabeled
oligonucleotide containing a GRE sequence were subject to the experimental design shown in A. B. Aliquots for each treatment were loaded into a
running gel and images were analyzed. C. Dissociation curves (mean 6 S.E.) from three independent experiments show the fraction bound (relative
to time zero) expressed as the ratio between GR-DNA complexes and free DNA probe. The arrows indicate the free DNA and the GR-DNA complexes.
doi:10.1371/journal.pone.0013279.g004
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performed GR-ligand/TIF2 coimmunoprecipitation assays.
BHK cells were co-transfected with hGR and TIF2 expression
vectors and treated with different ligands. Subsequently, protein
extracts were precipitated with a specific TIF2 antibody. Figure 5B
shows Western blot analysis performed against GR. Results
indicate that GR-21OH-6,19OP complex is not able to interact
with the coactivator (Figure 5B, lane 4) while GR-Dex, GR-21HS-
6,19OP and even GR-RU486 complexes bind TIF2 (Figure 5B,
lanes 3, 5 and 6, respectively). Interestingly, these interactions were
severely impaired in the presence of ethidium bromide throughout
the precipitation reaction (Figure 5C), suggesting DNA-mediated
protein association [62] between GR-ligand complexes and TIF2.
Taken together, these results indicate that while 21OH-6,19OP
affects GR’s ability to physically interact with TIF2, the other
ligands allow this interaction mainly in a DNA dependent manner.
As GR-RU486 binds TIF2 without inducing MMTV transcrip-
tion, we propose that this ligand would generate a non-functional
complex. Thus, different mechanisms of action should be
considered to explain 21OH-6,19OP and RU486 antagonism.
Molecular dynamics simulation of GR LBD-ligand
complexes
In order to investigate the molecular determinants of the Co-IP
results, particularly the GR LBD-21OH-6,19OP inability to
recruit TIF2, we carried out further MD simulations of GR
LBD-ligand complexes bound to a peptide corresponding to the
TIF2 coactivator.
The GR LBD-Dex complex (pdb:1n2z) has been crystallized
together with a peptide derived from TIF2 [12]. In this structure
the AF-2 domain and the TIF2 peptide interact through a
hydrophobic groove conformed by GR helices H3, H4 and H12
(Figure 6A) and the leucine residues of the helical LxxLL motif.
Additional electrostatic interactions termed ‘‘charge clamp’’,
between the GR aminoacid side chains (residues Lys579,
Glu755, Arg585 and Asp590) and the peptide are also involved
in GR LBD-coactivator complexes orientation and stability.
We constructed the four GR LBD-ligand/TIF2 complexes in
silico (see ‘‘Materials and Methods’’) and ran 20 ns MD simulations
for each case. The trajectories of all complexes show that the
global structure of the protein is reasonably stable (Figure S2A and
S2B). In order to evaluate the interactions between the GR LBD
and the TIF2 peptide we analyzed distances between atoms from
residues Lys579, Glu755, Arg585 and Asp590 and atoms from the
TIF2 peptide that in principle, may form hydrogen bond
interactions (Figure 6A). We found that GR LBD Asp590 often
interacts with TIF2 A746 without significant differences among
the four complexes. Interestingly, according to previous results this
interaction plays a key role in the specificity of the GR LBD to
bind the third TIF2 LxxLL motif [12]. We also observed that
Figure 5. 21OH-6,19OP-GR complex does not interact with
TIF2. A. BHK21 cells were cotransfected with MMTV-Luc vector in the
presence (+TIF2) or absence (-TIF2) of pTIF2 expression vector. pCMV-
LacZ vector were also introduced. Cells were incubated for 18 h with
ethanol (Control), 10 nM Dex, 10 mM 21OH-6,19OP, 10 mM 21HS-
6,19OP, and 1 mM RU486. Luciferase activity was determined and
normalized against b-galactosidase activity. Values are expressed as fold
induction relative to controls. Means 6 S.E. from three independent
experiments are shown. Bars with different superscript letters are
significantly different from each other (P ,0.05). B–C. BHK21 cells
cotransfected with pRSV-hGR and pTIF2 vectors were incubated with
the indicated steroids for 90 min at 37 C. Cytosols were extracted and
treated (or not) with ethidium bromide (BrEt) when indicated. TIF2-
associated GR was analyzed as described in ‘‘Materials and Methods’’.
Immunoadsorptions were performed with TIF2 antibody (a ´TIF2). Inputs
correspond to 10% of the sample previously to the immunoprecipita-
tion protocol. Western blotting was performed with a mixture of
antibodies against human GR. Arrows on input gel indicate the three
isoforms of a ´GR (GRA;G R B;G R C as previously described [21,91]). Gels
correspond to one representative experiment (n=3). Mean 6 SE values
of Immunoprecipitated (IP) GR levels (relative to Dex) are shown.
doi:10.1371/journal.pone.0013279.g005
GR Activity Modulation
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K751) in all GR LBD-ligand/TIF2 complexes. On the other
hand, only GR-21HS-6,19OP/TIF2 complex forms a hydrogen
bond between Arg585 and the TIF2 backbone atoms.
The major differences among the complexes were observed for
the Glu755 and TIF2 peptide interaction (Figure 6A, amplified
box). Figure 6B histogram shows that in the Dex system distances
between Glu755 CZ atom and N atoms of A743 and L744 are
approximately 4 A ˚, indicating a strong and stable interaction
among these residues. In the 21HS-6,19OP system (green), while
CZ (Glu755) – N (L744) distance is also around 4 A ˚; CZ (Glu755) –
N (A743) distance is smaller, indicating a stable interaction between
Glu755 and TIF2 when the agonist 21HS-6,19OP is bound.
Instead, in the presence of the antagonist 21OH-6,19OP (blue) the
histograms show that the distances are always higher, suggesting
that Glu755 does not interact with the coactivator.
In order to study GR LBD-RU486/TIF2 complex, we first
needed to evaluate GR LBD-RU486 behavior. At present, two x-
ray structures of GR LBD bound to RU486 have been reported
[17]; however none of them can be used as starting point for the
Figure 6. MD simulation of GR LBD-ligand/TIF2 complexes. A. AF-2 domain (green) is formed by helices H3, H4 and H12. GR LBD residues
from Glu755, Lys579 and Arg585 have electrostatic interactions with the TIF2 coactivator backbone (violet). Asp590 residue has electrostatic
interactions with the lateral side chain of TIF2 R746 residue. The figure also shows TIF2 leucines interacting hydrophobically with the GR LBD. This
image is derived from the pdb:1 m2z crystal structure. B. Histograms of the distances between the Glu755 CZ carbon atom of GRLBD and A743 N
atom or L744 N atom of TIF2 peptide. GR LBD-Dex/TIF2 (red), GR LBD-21OH-6,19OP/TIF2 (blue), GR LBD-21HS-6,19OP/TIF2 (green), GR LBD-RU486/
TIF2 (brown).
doi:10.1371/journal.pone.0013279.g006
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resolved [13] while in the recent x-ray structure pdb:1 h52 the GR
LBD is partially unfolded [23]. Therefore, we performed the MD
simulation of GR LBD-RU486 complex starting from the active
conformation of the receptor (pdb:1 m2z), which also allowed
direct comparison with the rest of GR-ligand/TIF2 complexes.
When the RU486 molecule is introduced in silico into the GR
LDB, atoms from the 11-substituent diethyl amino group and
Leu753 (H12) side chain atoms overlap (see ‘‘Materials and
Methods’’ and Figure S3B). However, taking into account the
recently obtained PR LBD-RU486 complex crystal structure
(pdb:2w8y) [24] (Figure S3A), where helix 12 is positioned in a
similar way as that observed for the agonist complex GR LBD-
Dex (pdb:1 m2z) [12], we introduced this ligand into the GR LBD
by rotating the Leu753 side chain in order to avoid unfavorable
steric interactions between the C-11 substituent in RU486 and the
GR LBP atoms, obtaining in this way a GR LBD-RU486 initial
complex able to be used in the MD simulation (Figure S3B).
Starting from this structure we performed 30 ns MD simulations
for the corresponding complex. The root mean squared deviation
(rmsd) from the initial structures measured over the backbone
atoms of GR LBD-RU486 complex reveals that during the first 20
ns the system undergoes important conformational changes,
resulting in the expansion of the receptor to accommodate the
RU486 voluminous molecule (Figure S3C). Visual inspection of
the GR LBD-RU486 trajectory shows that the main conforma-
tional changes occur in H12. During the first 3.5 ns the rmsd
values for all H12 backbone atoms increased abruptly compared
to the initial structure (Figure 7A), indicating a rapid RU486-
induced destabilization of this helix. After this fast change, until 15
ns the rmsd remained essentially stable (average value=1.61 A ˚).
However, from 15 ns to 20 ns another H12 conformational change
occurred with an rmsd decrease. Finally, from 20 ns to 30 ns H12
acquires a new stable conformation (average rmsd=1.12 A ˚).
Particularly from 5 to 15 ns, residues surrounding Ile756 loose
their helical motif. The time evolution of the psi756 angle confirms
that during this period dihedral values are not compatible with a
helical structure (Figure 7B). However, on the last 10 ns simulation
psi756 returns to values compatible with a helical structure.
Additionally, from 5 to 15 ns the H12 is displaced and partially
distorted with respect to the original conformation (Figure 7C).
The structural basis for this distortion would reside in the fact that
in order to accommodate the bulky moiety of RU486, H12 moves
away from the ligand and particularly, residues 756–757 loose the
helical motif. Interestingly, C-terminal residues acquire a helix
motif, similar to that observed previously in both GR LBD-rigid
steroid complexes [47,48]. By comparing the distorted structure
with a representative structure from the last 10 ns (Figure 7D) we
observed that although H12 remains around the same position,
residues 756–757 recover their helical motif. Taken together, these
Figure 7. MD simulation of GR LBD-RU486 complex. A. Root mean squared deviation (rmsd) from the initial structure measured over the H12
(751–766) backbone atoms of the GR LBD-RU486 complex. B. Time evolution of psi756 angle. C. Superposition of the initial structure (green) of GR
LBD-RU486 complex with the structure at 15 ns (blue). D. Superposition of the structures at 15 ns (blue) and at 30 ns (red).
doi:10.1371/journal.pone.0013279.g007
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RU486 by unwinding H12 specific residues and then stabilizing
the helical motif in a different conformation.
Finally, MD studies of receptor-coactivator interaction were
completed by the simulation of GR LBD-RU486/TIF2 complex,
starting from the same initial structure as the other GR LBD-
ligand/TIF2 complexes. Two main populations were found: one
with short distance values between GR Glu755 and TIF2
corresponding to the first half simulation period; and the other
with a larger distance corresponding to the second half period
(Figure 6B, brown). Therefore, results show that when GR binds
RU486, Glu755 and TIF2 form transient hydrogen bonds. B-
factor values of backbone atoms in the four complexes were then
calculated (Figure S4). Again, results show that the two antagonist
ligands induce a larger TIF2 mobility compared to the agonist
ligands.
In summary, MD simulation predict that hydrogen bonds
between Glu755 (H12) and TIF2 are rapidly lost when 21OH-
6,19OP is bound, and this lack of interactions leads to an increased
fluctuation of the TIF2 peptide in comparison with GR-agonist
complexes. Thus, 21OH-6,19OP would favor TIF2 dissociation
from GR-LBD, consistently with Co-IP results (Figure 5B). The
MD simulations also show that the hemisuccinate moiety in 21HS-
6,19OP reverses the loss of receptor-coactivator interaction, in
agreement with the experimental results.
Discussion
In the present study we attempted to gain a deeper insight into
activity modulation of the GR. By using four steroid ligands with
different glucocorticoid activities we analyzed the effects of ligand
structure on the GR transcriptional behavior and consequently the
cellular glucocorticoid response. A precise characterization of the
molecular determinants involved in specific GR conformational
changes will contribute to understand the different GR mecha-
nisms of action and may improve the strategies to the rational
design of new selective drugs.
By comparing the behavior of different complexes, we observed
that they distribute differently into the nucleus. Previous published
studies [63,64] have shown that as GR-ligand complexes are
formed and translocated into the nucleus, they form focal domains
consisting of several receptor molecules. GR intranuclear
distribution would then depend on affinity-based differences
between ligands rather than on transcriptional activities [50].
Here, we confirmed that high affinity ligands such as Dex or
RU486 induce a highly punctuate distribution. On the contrary,
rigid analogs distribute homogeneously. Although GR affinity of
these steroids has not yet been determined, previous transactiva-
tion assays suggest that 21OH-6,19OP is a low affinity ligand,
since only high concentrations ([10 mM]) are able to block Dex
([10 nM]) activity [48]. On the other hand, the apparent highest
CV value of GR-21HS-6,19OP respect to the GR-21OH-6,19OP
could reside in the increased ligand affinity due to the presence of
the hemisuccinate moiety.
The ability of GR to homodimerize upon ligand binding was
originally proposed based on several in vitro studies [25–29,31–33],
but leaving some unanswered key questions regarding its
mechanism. Only recently in vivo dimerization of the receptor
was visualized directly by co-IPs [39] or FRET analysis [40], and
also through an elegant indirect experiment [36]. In this work, we
used for the first time the N&B technique to evaluate GR
dimerization in vivo. Interestingly, results indicate that most of GR
molecules form homodimers inside the nucleus. Consistently,
dimer formation was also visualized by fluorescence fluctuation
spectroscopy in Cos-1 cells transfected with RXR-LBD-GFP fusion
protein, obtaining similar results [65]. Furthermore, the GR
oligomerization process would be independent of intranuclear
distribution, since different GR distribution patterns showed
similar oligomerization states.
For a variety of transcription factors, the route of DNA-protein
assembly has been described by two main mechanisms: the dimer
pathway, where transcription factors interact to DNA as homodi-
mers; and the monomer pathway where two monomers bind DNA
sequentially and assemble their dimerization interface while bound
to DNA [66,67]. Particularly on GR, it is still a debate issue
whether GR homodimers are formed before or as a result of GRE
binding. In this sense, some studies supported the monomer pathway
hypothesis [30,31,33] while other studies provided evidences of
GRE-independent dimer formation [25–29,39,40,68]. In the N&B
assays there is a large amount of GFPGR molecules due to
overexpression, thus it is unlikely that enough active GREs at a
given time point would be accessible to bind all GR molecules.
Although we can not establish whether GR binds DNA as a dimer
and/or as a monomer, results presented here support the idea that
GR could form homodimers in vivo in a DNA-independent fashion.
In agreement, Savory et al. suggested the possibility of GR
homodimerization occurring during or even before the transloca-
tion process [36]. Furthermore, taking into account that
homodimer formation is feasible even among non-functional
complexes, according to our results the dimerization step would
not be sufficient to define the GR as an active transcription factor.
MD simulation results led us to propose that the GR-21OH-
6,19OP complex would be unable to homodimerize [47].
However, experimental studies performed here indicate that
GR-21OH-6,19OP is able to form homocomplexes inside the
nucleus of living cells. In this sense, considering functional assays
which demonstrate that 21OH-6,19OP is unable to induce direct
transactivation but it induces monomer transcriptional activities,
we do not discard the possibility that dimers generated upon
21OH-6,19OP binding could acquire a conformation unable to
fully activate GR-gene activating properties. Since the ability to
induce transcription depends, at least in part, on the ligand-
induced interaction with coactivators, one might postulate that the
reduced transcriptional activation by a dissociated compound
should indicate an impaired recruitment of coactivators. However,
this hypothesis has not been investigated for most of the GR
ligands [69]. In this sense, Co-IP assays demonstrated that GR-
21OH-6,19OP is unable to recruit TIF2, explaining at least in
part the molecular mechanism of action for this selective
glucocorticoid. Therefore, in the presence of 21OH-6,19OP it
is possible that GR AF-2 domain may adopt a conformation
unable to bind TIF2 or that GR-21OH-6,19OP homocomplex
may be blocked due to the binding to other proteins that impede
cofactor recruitment. According to EMSAs results, this confor-
mation would not affect the capacity of GR to bind to specific
GREs, as all GR-ligand complexes are able to bind MMTV
probe in vitro. In addition, the fact that GR-21OH-6,19OP
complex is able to dimerize without recruiting TIF2 coactivator
suggests that GR homodimers could be formed independently of
cofactor interaction.
As mentioned above, agonist-complexes place Helix 12 in a
permissive conformation able to bind TIF2 coactivator. In this
sense, we observed that GR-TIF2 complex precipitates in vivo upon
Dex or 21HS-6,19OP addition and both GR-agonist complexes
increase their transactivation activities upon TIF2 overexpression.
Although MD simulations allow us to investigate the molecular
basis of dissociation rather than association mechanisms, results
are consistent with the above experimental data since stable
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plexes were observed. On the other hand, MD simulation showed
that hydrogen bonds between Glu755 (H12) and TIF2 are rapidly
lost when 21OH-6,19OP is bound. In consequence, this lack of
interaction leads to an increase fluctuation of the TIF2 peptide in
comparison with the other GR-ligand complexes. Consistently,
previous studies had shown that E755A and E755R mutations
strongly compromise GR-Dex to recruit coactivators and hence to
induce transactivation [12].
The MD study of GR LBD-RU486 complex showed that the
presence of RU486 is sterically compatible with an H12 agonist
position. These results may explain some agonistic actions of
RU486 described elsewhere [20]. As it was observed in the PR
LBD-RU486 complex [24], significant H12 conformational
changes of GR LBD occur in order to accommodate the bulky
moiety of RU486. This agrees with the idea of a dynamic model in
which RU486 does not induce one particular receptor conforma-
tion, but works through changing H12 dynamic equilibrium.
Accordingly, Co-IPs results indicate that GR-RU486 complex is
able to interact with TIF2. Thus, it is possible that this ligand
might generate a non-functional GR/TIF2 complex or that its
antagonistic effect would reside on its ability to modulate the
dynamics of GR-DNA interaction as previously suggested [60]
and confirmed here. We conclude that 21OH-6,19OP and
RU486 antagonize GR by different mechanisms. These results
could also imply that while TIF2 recruitment may be necessary for
GR transactivation activity at least on the MMTV model [70,71],
it appears not to be sufficient.
In view of the variety of physiological processes in which
glucocorticoids are involved, from a pharmacological standpoint
selective antiglucocorticoids that can block only some of these
processes would be highly desirable. Interestingly, transactivation
and transrepression studies suggest that 21OH-6,19OP conserves
the so-called beneficial glucocorticoid properties while behaving as
an antiglucocorticoid in unwanted actions. Nevertheless, increasing
evidence suggests that glucocorticoid action could be classified in
terms of GR-interacting coregulators rather than transactivation/
dimer or transrepression/monomer activities. It is a currently
accepted theory that both the identity and relative expression of
coactivators and corepressors influence the ability of ligands to
regulate gene expression [72]. Therefore, selective recruitment of
specific coactivator subsets by determined GR conformations
acquired upon ligand binding is likely to represent a promising
goal into the design of new selective glucocorticoids.
Materials and Methods
Steroids and reagents
21OH-6,19OP and 21HS-6,19OP were prepared as previously
described [73]. Dex and RU486 were purchased from Sigma and
Dulbecco’s modified Eagle’s medium (DMEM) was from Invitrogen.
Fetal calf serum (FCS) was purchased from Internegocios S.A. FCS
was delipidated with charcoal-dextran as previously described [74].
Cell culture and transient transfection assays
Cos-7, L929 and BHK21 cells were cultured in DMEM
supplemented with 10% FCS plus penicillin (100 IU/ml) and
streptomycin (100 mg/ml) at 37 C under humidified atmosphere
with 4.5% CO2. Transient transfections were performed with
Lipofectin 2000 (Invitrogen) according to manufacturer’s instruc-
tions. After transfection, cells were incubated in DMEM
containing 5% charcoal-stripped FCS and the corresponding
steroids from 1000-fold stock solutions as indicated in each
experiment.
Transactivation and transrepression assays
3610
4 BHK cells were co-transfected with 0.3 mg pMMTV-
luciferase vector [75] and 0.3 mg pTIF2 [76] or equal amounts of
non-coding vector. For NFkB and AP-1 transrepression assays,
0.3 mg pkB-luciferase [77] and 0.1 mg pRelA vectors [78], or
0.3 mg pAP1- luciferase [79] and 0.1 mg pcJun [80] vectors were
used. 0.2 mg pCMV-LacZ was added as control. Luciferase
activity was measured according to the manufacturer’s protocol
(Promega Inc. cat # E1501). a ˆ-galactosidase activity was measured
as previously described [81].
Subcellular localization, intranuclear distribution and
N&B analysis
3610
5 cells were transfected with 1 mg of pEGFPGR [49] or the
empty vector pEGFP-C3 (Clontech) and incubated with the
corresponding steroids for at least 40 minutes. Next, the medium
was replaced with RAB buffer (Hepes 10 mM pH 7.4; NaCl
135 mM, KCl 10 mM, MgCl2 0.4 mM; CaCl2 1 mM; Glucose
1%) supplemented with the indicated steroids and then analyzed
by confocal fluorescence microscopy. All measurements were done
in a FV1000 confocal laser scanning microscope (Olympus), with
an Olympus UPlanSApo 606oil immersion objective (NA=1.35).
The excitation source was a multi-line Ar laser tuned at 488 nm
(average power at the sample, 700 nW). Fluorescence was detected
with a photomultiplier set in the pseudo photon-counting
detection mode.
For intranuclear analysis, images of 5126512 pixels (pixel size
0.1 mm; pixel dwell time 20 ms) were taken, except for the
representative pictures shown in Figure 1 (102461024 pixels).
Coefficient of variation (CV) was calculated as described elsewhere
[50]. The higher the CV value, the more nonrandom the
distribution is. In each treatment, at least 20 cells were randomly
selected and their CV values were averaged.
N&B measurements were done as previously described [53,82]
with some modifications. Briefly, for each studied cell a stack of
200 images (2566256 pixels) were taken in the conditions
mentioned above, setting the pixel size to 82 nm and the pixel
dwell time to 10 ms. Each stack was further analyzed using the
N&B routine of the ‘‘GLOBALS for Images’’ program developed
at the Laboratory for Fluorescence Dynamics (UCI, Irvine, CA).
In this routine, the average fluorescence intensity (Ækæ) and its
variance (s
2) at each pixel of an image are determined from the
intensity values obtained at the given pixel along the images stack.
The apparent brightness (B) is then calculated as the ratio of s
2 to
Ækæ while the apparent number of moving particles (N) corresponds
to the ratio of Ækæ to B. In a previous work it has been
demonstrated that B is equal to the real brightness e of the
particles plus 1 [53]. Therefore, e at every pixel of images can be
easily extracted from B measurements. Importantly, this analysis
only provides information regarding to the moving or fluctuating
fluorescent molecules since fixed molecules will give B values equal
to 1. Figure S5 shows an example of the analysis followed to
determine the average brightness of GFPGR at each subcellular
compartment.
Electro mobility shift assay (EMSA)
EMSAs were performed with the previously described 33-bp
MMTV GRE oligonucleotide probe [28]. The complementary
strands were annealed in equimolar amounts (100 nM each) on
10 mM Tris-HCl pH 8; 1 mM EDTA; 30 mM KCl by
denaturating at 95 C for 10 min and cooling down to room
temperature. Double-stranded oligonucleotides were radiolabeled
with T4 polynucleotide kinase (Invitrogen) and 50 mCi [c
32P]
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For binding studies, reactions were carried out in 25 ml reaction
buffer (5 mM Tris-HCl, pH 8, 0.5 mM EDTA, 5% glycerol,
0.5 mM 2-mercaptoethanol, 1 mg poly(dI-dC), 90 ng Calf thymus
DNA, and 30 mg BSA), 10 ng of radiolabeled probe and 200-fold
excess of unlabeled specific or unspecific probe when indicated.
Three micrograms of the nuclear extract were added to the
binding reaction and incubated for 20 min at room temperature.
Then, reaction mixtures were subjected to 6% acrylamide gel in
Tris-Borate-EDTA solution. For dissociation studies, reactions
were carried out in 100 ml reaction buffer containing 50 ng of
radiolabeled probe and 18 mg of nuclear extract. After 20 minutes
incubation at room temperature, 200-fold unlabeled probe was
added and reaction aliquots (16 ml) were loaded at different times
into a gel running at 200 V. Images were taken with STORM 820
PhosphorImager and analyzed with NIH-Image J v1.63 software
analysis.
Coimmunoprecipitation and western blot
2610
6 BHK cells co-transfected with 5 mg pRSV-hGR [84] and
5 mg pTIF2 were incubated with the corresponding steroids for
90 min at 37 C. Then, cells were lysed with CytoBuster Protein
Extraction Buffer (EMD Biosciences) supplemented with Protease
inhibitor cocktail (Calbiochem) and clarified by centrifugation at
13000 rpm for 5 min. Protein extracts (1 mg per treatment) were
pre-cleared with protein A/G plus agarose solution (Santa Cruz
Biotechnology; sc-2003). Samples were mixed by rotation for 1 h
at 4 C and centrifuged for 2 min at 13000 rpm. Supernatants were
immunoprecipitated with TIF2 antibody (Santa Cruz Biotechnol-
ogy, sc-8996) and protein A/G plus agarose solution. Samples
were then mixed by rotation for 4 h at 4 C and centrifuged for
3 min at 13000 rpm. Pellets were washed three times with TEGM
buffer (10 mM HEPES pH 7.5, 1 mM EDTA, 20 mM Na2-
MoO4, 5% glycerol, 50 mM NaCl) and centrifuged for 3 min at
13000 rpm. Proteins were extracted with SDS sample buffer,
separated by 7% SDS-PAGE and transferred to PVDF membrane
(Bio-Rad) by electroblotting. Immunodetection was achieved with
a 1:1 mixture of GR antibodies (Santa Cruz Biotechnology, sc-
1002; sc-1003).
Coimmunoprecipitation in the presence of Ethidium
bromide
Cells were lysed with CytoBuster Protein Extraction Buffer as
described above. Then, Ethidium Bromide (100 mg/ml) was added
to 200 ml of lysed material, followed by incubation for 1 h on ice.
Then, after 5 min centrifugation at 13,000 rpm supernatants were
collected and used for TIF2-GR immunoprecipitation as described
above, with the exception that the immunoprecipitated material
was then washed three times with TEGM buffer supplemented
with Ethidium Bromide (100 mg/ml).
Quantum Mechanics Calculations
The geometry of the ligands Dex, 21OH-6,19OP, 21HS-
6,19OP and RU486 were optimized using the ab initio quantum
chemistry program Gaussian 03 [85] and the HF/6-31G** basis
set. RESP (restraint electrostatic potential) atomic charges were
derived for all ligands using the optimized geometries.
In silico construction of GR LBD-ligand/TIF2 complexes
The GR LBD-ligand/TIF2 complexes were built starting from
the GR LBD-Dex complex (pdb:1 m2z) crystal structure using
both the Chain A (corresponding to the receptor) and the Chain B
(residues 759 to 773 corresponding to the TIF2 peptide). 21OH-
6,19OP and 21HS-6,19OP were introduced within the GR LBD/
TIF2 complex superimposing carbon atoms of ring C with the
corresponding atoms of the Dex molecule in the GR LBD-Dex/
TIF2 complex. The RU486 molecule was introduced similarly to
the GR LBD-RU486 complex described below.
In silico construction of GR LBD-RU486 complex
To introduce the RU486 within the GR LBD, the chain A of
the crystal GR LBD-Dex complex (pdb:1 m2z) was superimposed
with the crystal structure of the GR LBD-RU486 complex
(pdb:1 nhz) using the VMD program [86]. Then, the crystalized
RU486 molecule was replaced for the optimized RU486 structure
by superimposing the corresponding carbon atoms of the C ring.
These RU486 coordinates and GR LBD pdb:1 m2z coordinates
were used to construct the complex. When the RU486 molecule is
introduced in this way in the GR-LDB, 11-substituent diethyl
amino group atoms and Leu753 (H12) side chain atoms overlap
giving rise to sterical clashes (Figure S3B). To resolve these clashes
Leu753 side chain was rotated using the Deep-view/Swiss-
pdbviewer program [87] until Leu753 (orange) side chain acquired
a similar conformation as the corresponding residue (Met909) of
the PR LBD-RU486 complex [24] (Figure S3A). Final accom-
modation of RU486 diethyl amino group and Leu753 side chain
was achieved by geometry optimization.
Molecular Dynamics Simulations
MD simulations were performed by using the AMBER 9
software package [88]. The complexes were immersed in an
octahedral box of TIP3P water molecules using the Leap module.
The Amber99 force field parameters were used for all protein
residues [89] and ligand parameters were assigned with the
general AMBER force field (GAFF) and the corresponding RESP
charges using the Antechamber module of AMBER. The systems
were initially optimized and then gradually heated to 300 K.
Starting from these equilibrated structures, MD production runs of
30 ns for GR LBD-RU486 complex and 20 ns for the GR LBD-
ligand/TIF2 complexes were performed. All simulations were
performed at 1 atm and 300 K, maintained with the Berendsen
barostat and thermostat [90] using periodic boundary conditions
and the particle mesh Ewald method (grid spacing of 1 A ˚) for
treating long-range electrostatic interactions, with a uniform
neutralizing plasma. The SHAKE algorithm was used to keep
bonds involving H atoms at their equilibrium length, allowing us
to employ a 2 fs time step for the integration of Newton’s
equations. The analysis of the trajectories was performed with the
Ptraj module of Amber and the visualization of the structures with
the VMD program [86].
Statistical Analysis
Results were expressed as means 6 standard error. Statistical
analyses were performed with STATISTICA 6.0 (StatSoft, Inc.)
and consisted of one- or two-way ANOVA followed by Tukey’s
multiple comparisons tests. Differences were regarded as signifi-
cant at P,0.05. Before statistical analysis, data were tested for
normality and homoscedasticity using Lilliefors and Bartlett’s tests,
respectively. In some cases, log-transformed or roothsquare-
transformed data were used. In all cases, bars with different
superscript letters are significantly different from each other.
Supporting Information
Figure S1 Ligand effect on GFPGR transcriptional activity and
nuclear translocation. A. Transactivation assays. BHK21 cells
were cotransfected with pEGFPGR and MMTV-Luc reporter
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incubated for 18 h with the indicated steroids combination at the
following final concentrations: ethanol and/or DMSO (Control),
10 nM Dexamethasone (Dex), 10 mM 21-Hydroxy-6,19-epoxy-
progesterone (21OH-6,19OP), 10 mM 21-succinoyloxy-6,19-epox-
yprogesterone (21HS-6,19OP), and 1 mM mifepristone (RU486).
Luciferase activity was measured. After correcting for b-galacto-
sidase activity, values were expressed as fold induction relative to
the control. Means 6 S.E. from three independent experiments
are shown. ANOVA test were not performed because homosce-
dasticity could not be achieved. Instead, a t-student test was
carried out only between two pairs of treatments. Thus, bars with
different superscript letters (a vs. b and c vs. d) are significantly
different from each other (P ,0.05). B. Cellular localization of
GFPGR molecules. Cos-7, L929, and BHK21 cells transfected
with pEGFPGR were incubated with the indicated steroids for
40 min at 37uC as described in ‘‘Materials and Methods’’. Cells
were visualized by confocal scanning microscopy. Scale bar = 20
mm. The figure shows representative cells for each treatment. In
the upper left side of dex treated L929 cells it shows GFP
transfected cells showing homogeneous distribution throughout
the cell. Note that the GR-complex does not seem to translocate
completely in the presence of 21OH-6,19OP.
Found at: doi:10.1371/journal.pone.0013279.s001 (3.37 MB TIF)
Figure S2 Stability of GR-ligands - TIF2 complexes during the
30 ns simulation. Root mean squared deviation (rmsd) from the
initial structure measured over the backbone atoms of the GR
LBD-dex/TIF2 (red), GR LBD-21HS-6,19OP/TIF2 (green) (A),
or GR LBD-21OH-6,19OP/TIF2 (blue) and GR LBD-RU486/
TIF2 (brown) (B).
Found at: doi:10.1371/journal.pone.0013279.s002 (0.95 MB TIF)
Figure S3 In silico introduction of RU486 into the GR LBD and
stability of the complex during simulation. A. In the PR LBD-
RU486 crystal structure (pdb:2w8y), the RU486 diethyl amino
group occupy the space between Met909 and H3. B. When the
RU486 molecule is introduced in silico in the GR-LDB, 11-
substituent diethyl amino group atoms (Cyan: carbon; Red:
Oxygen; Blue: Nitrogen) and Leu753 (H12) side chain atoms
(green) overlap giving rise to sterical clashes. To resolve these
clashes Leu753 side chain was rotated using the Deep-view/Swiss-
pdbviewer program [87] until Leu753 (orange) side chain acquired
a similar conformation as the corresponding residue (Met909) of
the PR LBD-RU486 complex [24]. Final accommodation of
RU486 diethyl amino group and Leu753 side chain was achieved
by geometry optimization. C. Root mean squared deviation (rmsd)
from the initial structure measured over the backbone atoms of the
GR LBD-RU486 complex.
Found at: doi:10.1371/journal.pone.0013279.s003 (5.54 MB TIF)
Figure S4 TIF2 fluctuation within the GR LBD-ligand
complexes. B-factor of the TIF2 backbone atoms in the GR
LBD-Dex/TIF2 (red), GR LBD-21HS-6,19OP/TIF2 (green), GR
LBD-21OH-6,19OP/TIF2 (blue) and GR LBD-RU486/TIF2
(brown) complexes.
Found at: doi:10.1371/journal.pone.0013279.s004 (0.42 MB TIF)
Figure S5 Measurement of GFPGR molecule brightness. A.
Picture of a representative cell treated with 21OH-6,19OP. B. As
described in ‘‘Materials and Methods,’’ the average fluorescence
intensity and its variance at each pixel of an image are determined
from the intensity values obtained at the given pixel along the
images stack. The apparent brightness (B) is then calculated as the
ratio of the average fluorescence intensity and its variance. For
stimulated cells, the fluorescence intensity at the nucleus was
higher than the intensity at the cytosol. Therefore we applied an
intensity threshold to calculate separately the average value of B in
both cell regions. For unstimulated cells, B values were calculated
in squared regions which only included points of the cytoplasm or
the nucleus. The figure shows the B values histogram for two
regions of a representative stimulated-cell. The left-shifted
histogram (blue) corresponds to the cytoplasmic region (red spots,
left cell box). The right-shifted histogram (black) corresponds to
the nucleus (red spots, right cell box). The mean of each Gaussian-
fit histogram is the B value for each cell compartment. Note that B
values from the nucleus are in average higher than cytoplasmic
values. This indicates a higher oligomerization state in the nucleus
respect to the cytoplasm. Finally, e (real brightness) is B minus 1
[53].
Found at: doi:10.1371/journal.pone.0013279.s005 (2.20 MB TIF)
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